Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis

Liver International

Volumn 32, Issue 6, 2012, Pages 919-927

  Senzolo, Marco ^a   Sartori, Teresa M ^b   Rossetto, Valeria ^b   Burra, Patrizia ^a   Cillo, Umberto ^a   Boccagni, Patrizia ^a   Gasparini, Daniele ^c   Miotto, Diego ^a   Simioni, Paolo ^b   Tsochatzis, Emmanuel ^d   Burroughs, Kenneth A ^d  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cirrhosis; Coagulation; Portal hypertension; Portal vein thrombosis; Thrombophilia

Indexed keywords

NADROPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; EPISTAXIS; FEMALE; HEMATURIA; HUMAN; INTESTINE ISCHEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PROSPECTIVE STUDY; STOMACH VARICES BLEEDING; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME;

ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPERTENSION, PORTAL; ITALY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PORTAL PRESSURE; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84861970773     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02785.x     Document Type: Article

References (24)

1. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992; 16: 1195-8.
2. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-74.
3. Zocco MA, Di SE, De CR, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51: 682-9.
4. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-8.
5. Mangia A, Villani MR, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17: 745-51.
6. Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010; 16: 83-90.
7. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-41.
8. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000; 32: 865-71.
9. Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23: 767-75.
10. Senzolo M, Patch D, Miotto D, et al. Interventional treatment should be incorporated in the algorithm for the management of patients with portal vein thrombosis. Hepatology 2008; 48: 1352-3.
11. Condat B, Pessione F, Helene DM, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32: 466-70.
12. Plessier A, Rwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51: 210-8.
13. Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-51.
14. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.
15. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-7.
16. Amitrano L, Brancaccio V, Guardascione MA, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535-8.
17. Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42: 163-70.
18. Garcia-Fuster MJ, Abdilla N, Fabia MJ, et al. [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008; 100: 259-62.
19. Brigden ML, Kay C, Le A, Graydon C, Mcleod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998; 59: 22-7.
20. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-13.
21. Reisner EH Jr, Norman J. The effect of liver dysfunction on the response to dicumarol. Am J Med Sci 1949; 217: 445-7.
22. Trotter JF, Olson J, Lefkowitz J, et al. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007; 7: 1624-8.
23. Primignani M, Era AD, Fabris FM, et al. High incidence of heparin induced thrombocytopenia (HIT) in splanchnic vein thrombosis treated with low weight molecular heparin (LWMH). Am J Transplant 2008; 48(suppl. 2): p. S113.
24. Senzolo M, Burra P, Patch D, Burroughs AK. Tips for portal vein thrombosis (PVT) in cirrhosis: not only unblocking a pipe. J Hepatol 2011; 55: 945-6.